WeLeader Biomedical Co., Ltd. (TPEX:7713)

Taiwan flag Taiwan · Delayed Price · Currency is TWD
67.20
+0.10 (0.15%)
May 29, 2026, 1:30 PM CST
Market Cap3.06B +16.3%
Revenue (ttm)1.14B +14.2%
Net Income220.57M +32.1%
EPS4.62 +16.8%
Shares Out 45.48M
PE Ratio14.53
Forward PEn/a
Dividend4.10 (6.10%)
Ex-Dividend DateMar 27, 2026
Volume24,178
Open66.90
Previous Close67.10
Day's Range66.90 - 67.70
52-Week Range57.50 - 83.00
Beta0.10
Analystsn/a
Price Targetn/a
Earnings DateAug 12, 2026

About WeLeader Biomedical

WeLeader Biomedical Co., Ltd. operates as an agent and distributor of in vitro diagnostic products. It offers a range of medical testing systems, such as serum biochemistry integration platform, clinical care, and medical information integration system. The company also provides blood gas electrolyte analyzers, urine analyzers, integrated fully automatic biochemical analyzers, fully automatic electronic luminescence immunoassay products, fully automatic modular biochemical immune assay products, TTA automated pre-processing products, POCT centr... [Read more]

Sector Healthcare
Founded 1992
Country Taiwan
Stock Exchange Taipei Exchange
Ticker Symbol 7713
Full Company Profile

Financial Performance

In 2025, WeLeader Biomedical's revenue was 1.11 billion, an increase of 11.92% compared to the previous year's 991.13 million. Earnings were 208.56 million, an increase of 22.53%.

Financial Statements